Dual blockade of the renin–angiotensin–aldosterone system with high-dose angiotensin-converting enzyme inhibitor for nephroprotection: An open, controlled, randomized study

References

• Tylicki L, Larczynski W, Rutkowski B. Renal protective effects of the renin-angiotensin-aldosterone system blockade: from evidence-based approach to perspectives. Kidney Blood Press Res 2005; 28: 230–42
   PubMed Web of Science ®Google Scholar
• Tylicki L, Biedunkiewicz B, Chamienia A, Wojnarowski K, Zdrojewski Z, Rutkowski B. Randomized placebo-controlled study on the effects of losartan and carvedilol on albuminuria in renal transplant recipients. Transplantation 2006; 81: 52–6
   PubMed Web of Science ®Google Scholar
• Tylicki L, Biedunkiewicz B, Chamienia A, Wojnarowski K, Zdrojewski Z, Aleksandrowicz E, et al. Renal allograft protection with angiotensin II type 1 receptor antagonists. Am J Transplant 2007; 7: 243–8
   PubMed Web of Science ®Google Scholar
• Rutkowski P, Tylicki L, Renke M, Korejwo G, Zdrojewski Z, Rutkowski B. Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis. Am J Kidney Dis 2004; 43: 260–8
   PubMed Web of Science ®Google Scholar
• Renke M, Tylicki L, Rutkowski P, Wojnarowski K, Lysiak-Szydlowska W, Rutkowski B. Low-dose dual blockade of the renin-angiotensin system improves tubular status in nondiabetic proteinuric patients. Scand J Urol Nephrol 2005; 39: 511–7
   PubMed Web of Science ®Google Scholar
• Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361: 117–24
   PubMed Web of Science ®Google Scholar
• Brenner B. AMGEN International Prize: the history and future of renoprotection. Kidney Int 2003; 23: 1163–8
   Google Scholar
• Fogo AB. The potential for regression of renal scarring. Curr Opin Nephrol Hypertens 2003; 12: 223–5
   PubMed Web of Science ®Google Scholar
• Maroni BJ, Steinman TI, Mitch WE. A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int 1985; 27: 58–65
   PubMed Web of Science ®Google Scholar
• Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41
   PubMed Web of Science ®Google Scholar
• Maruhn D. Rapid calorimetric assay of b-galactosidase and N-acetyl-b-D-glucosaminidase in human urine. Clin Chim Acta 1976; 73: 453–61
   PubMed Web of Science ®Google Scholar
• Gansevoort R, De Zeeuw D, De Jong P. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?. Kidney Int 1994; 45: 861–7
   PubMed Web of Science ®Google Scholar
• Taal M, Brenner B. Combination ACEI and ARB therapy: additional benefit in renoprotection. Curr Opin Nephrol Hypertens 2002; 11: 377–81
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Remuzzi A. Is therapy with combined ACE inhibitor and angiotensin receptor antagonist the new gold standard of treatment for nondiabetic, chronic proteinuric nephropathies?. NephSAP 2003; 2: 235–7
   Google Scholar
• Forclaz A, Maillard M, Nussberger J, Brunner HR, Burnier M. Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor?. Hypertension 2003; 41: 31–6
   PubMed Web of Science ®Google Scholar
• Fogo AB. Regression lines in chronic kidney disease. J Am Soc Nephrol 2003; 14: 2990–1
   PubMedGoogle Scholar
• Peters H, Border W, Noble N. Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 1998; 54: 1570–80
   PubMed Web of Science ®Google Scholar
• Adamczak M, Gross M, Krtil J, Koch A, Tyralla K, Amann K, et al. Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol 2003; 14: 2833–42
   PubMed Web of Science ®Google Scholar
• Boffa JJ, Lu Y, Placier S, Stefanski A, Dussaule JC, Chatziantoniou C. Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol 2003; 14: 1132–44
   PubMed Web of Science ®Google Scholar
• Ma LJ, Nakamura S, Whitsitt JS, Marcantoni C, Davidson JM, Fogo AB. Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1. Kidney Int 2000; 58: 2425–36
   PubMed Web of Science ®Google Scholar
• Haas M, Leko-Mohr Z, Erler C, Mayer G. Antiproteinuric versus antihypertensive effects of high-dose ACE inhibitor therapy. Am J Kidney Dis 2002; 40: 458–63
   PubMed Web of Science ®Google Scholar
• Aranda P, Segura J, Ruilope LM, Aranda FJ, Frutos MA, Lopez V, et al. Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies. Am J Kidney Dis 2005; 46: 1074–9
   PubMed Web of Science ®Google Scholar
• Weinberg M, Weinberg A, Cord R, Zappe D. The effect of high-dose angiotensin II receptor blockade beyond maximal recommended doses in reducing urinary protein excretion. JRAAS 2002; 2(Suppl 1)S196–8
   Google Scholar
• Weinberg AJ, Zappe DH, Ashton M, Weinberg MS. Safety and tolerability of high-dose angiotensin receptor blocker therapy in patients with chronic kidney disease: a pilot study. Am J Nephrol 2004; 24: 340–5
   PubMed Web of Science ®Google Scholar
• Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 2005; 68: 1190–8
   PubMed Web of Science ®Google Scholar
• Muller GA, Zeisberg M, Strutz F. The importance of tubulointerstitial damage in progressive renal disease. Nephrol Dial Transplant 2000; 15(Suppl 6)76–7
   PubMedGoogle Scholar
• Bazzi C, Petrini C, Rizza V, Arrigo G, Napodano P, Paparella M, et al. Urinary N-acetylglucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis. Nephrol Dial Transplant 2002; 17: 1890–6
   PubMed Web of Science ®Google Scholar
• Holdt-Lehmann B, Lehmann A, Korten G, Nagel H, Nizze H, Schuff-Werner P. Diagnostic value of urinary alanine aminopeptidase and N-acetyl-beta-D-glucosaminidase in comparison to alfa-1 microglobulin as a marker in evaluating tubular dysfunction in glomerulonephritis patients. Clin Chim Acta 2000; 297: 93–102
   PubMed Web of Science ®Google Scholar
• Soylemezoglu O, Wild G, Dalley AJ, MacNeil S, Milford-Ward A, Brown CB, et al. Urinary and serum type III collagen: markers of renal fibrosis. Nephrol Dial Transplant 1997; 12: 1883–9
   PubMed Web of Science ®Google Scholar
• Teppo AM, Tornroth T, Honkanen E, Gronhagen-Riska C. Urinary amino-terminal propeptide of type III procollagen (PIIINP) as a marker of interstitial fibrosis in renal transplant recipients. Transplantation 2003; 75: 2113–9
   PubMed Web of Science ®Google Scholar